Prevention of chemotherapy induced nausea and vomiting: A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla

Kamalesh K. Sankhala, Devesh M. Pandya, John Sarantopoulos, Scott A. Soefje, Francis J. Giles, Sant P. Chawla

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Nausea and vomiting is one of the most feared side effects of chemotherapy; however, in the past 20 years, a better understanding of the pathophysiology of chemotherapy-induced nausea and vomiting (CINV) has led to the introduction of newer antiemetics, which have improved the management of this side effect. Objective: This article reviews the prevention of CINV and the role of aprepitant, the first of the newest class of antiemetics, the neurokinin-1 inhibitors. A brief description of the pathophysiology of CINV and the background on the prevention of CINV using the 5-HT3 antagonists is outlined. The pharmacology, pharmacokinetics, drug interactions and various clinical studies with aprepitant are reviewed. Methods: The literature about aprepitant is reviewed focusing on the role of aprepitant in the management of CINV in relationship to other commonly used antiemetics. The literature was searched regarding aprepitant and its pharmacological characteristics, pharmacokinetics, drug interactions and various clinical studies. Conclusion: Aprepitant has a significant role in the management of CINV, as it allows the majority of patients to complete their chemotherapies without significant morbidity. Its use in a variety of clinical settings in cancer patients needs to be further explored.

Original languageEnglish (US)
Pages (from-to)1607-1614
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume5
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

aprepitant
Chemotherapy
Nausea
Vomiting
Drug Therapy
Antiemetics
Drug interactions
Pharmacokinetics
Drug Interactions
Pharmacology
Serotonin 5-HT3 Receptor Antagonists

Keywords

  • Aprepitant
  • Chemotherapy-induced nausea and vomiting
  • Clinical studies
  • Drug interaction
  • Neurokinin-1 inhibitors
  • Pharmacokinetics
  • Pharmacology

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Prevention of chemotherapy induced nausea and vomiting : A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla. / Sankhala, Kamalesh K.; Pandya, Devesh M.; Sarantopoulos, John; Soefje, Scott A.; Giles, Francis J.; Chawla, Sant P.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 12, 12.2009, p. 1607-1614.

Research output: Contribution to journalArticle

Sankhala, Kamalesh K. ; Pandya, Devesh M. ; Sarantopoulos, John ; Soefje, Scott A. ; Giles, Francis J. ; Chawla, Sant P. / Prevention of chemotherapy induced nausea and vomiting : A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla. In: Expert Opinion on Drug Metabolism and Toxicology. 2009 ; Vol. 5, No. 12. pp. 1607-1614.
@article{77c404f6e4fb4ce3897c19ef33242cc5,
title = "Prevention of chemotherapy induced nausea and vomiting: A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla",
abstract = "Background: Nausea and vomiting is one of the most feared side effects of chemotherapy; however, in the past 20 years, a better understanding of the pathophysiology of chemotherapy-induced nausea and vomiting (CINV) has led to the introduction of newer antiemetics, which have improved the management of this side effect. Objective: This article reviews the prevention of CINV and the role of aprepitant, the first of the newest class of antiemetics, the neurokinin-1 inhibitors. A brief description of the pathophysiology of CINV and the background on the prevention of CINV using the 5-HT3 antagonists is outlined. The pharmacology, pharmacokinetics, drug interactions and various clinical studies with aprepitant are reviewed. Methods: The literature about aprepitant is reviewed focusing on the role of aprepitant in the management of CINV in relationship to other commonly used antiemetics. The literature was searched regarding aprepitant and its pharmacological characteristics, pharmacokinetics, drug interactions and various clinical studies. Conclusion: Aprepitant has a significant role in the management of CINV, as it allows the majority of patients to complete their chemotherapies without significant morbidity. Its use in a variety of clinical settings in cancer patients needs to be further explored.",
keywords = "Aprepitant, Chemotherapy-induced nausea and vomiting, Clinical studies, Drug interaction, Neurokinin-1 inhibitors, Pharmacokinetics, Pharmacology",
author = "Sankhala, {Kamalesh K.} and Pandya, {Devesh M.} and John Sarantopoulos and Soefje, {Scott A.} and Giles, {Francis J.} and Chawla, {Sant P.}",
year = "2009",
month = "12",
doi = "10.1517/17425250903451675",
language = "English (US)",
volume = "5",
pages = "1607--1614",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Prevention of chemotherapy induced nausea and vomiting

T2 - A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla

AU - Sankhala, Kamalesh K.

AU - Pandya, Devesh M.

AU - Sarantopoulos, John

AU - Soefje, Scott A.

AU - Giles, Francis J.

AU - Chawla, Sant P.

PY - 2009/12

Y1 - 2009/12

N2 - Background: Nausea and vomiting is one of the most feared side effects of chemotherapy; however, in the past 20 years, a better understanding of the pathophysiology of chemotherapy-induced nausea and vomiting (CINV) has led to the introduction of newer antiemetics, which have improved the management of this side effect. Objective: This article reviews the prevention of CINV and the role of aprepitant, the first of the newest class of antiemetics, the neurokinin-1 inhibitors. A brief description of the pathophysiology of CINV and the background on the prevention of CINV using the 5-HT3 antagonists is outlined. The pharmacology, pharmacokinetics, drug interactions and various clinical studies with aprepitant are reviewed. Methods: The literature about aprepitant is reviewed focusing on the role of aprepitant in the management of CINV in relationship to other commonly used antiemetics. The literature was searched regarding aprepitant and its pharmacological characteristics, pharmacokinetics, drug interactions and various clinical studies. Conclusion: Aprepitant has a significant role in the management of CINV, as it allows the majority of patients to complete their chemotherapies without significant morbidity. Its use in a variety of clinical settings in cancer patients needs to be further explored.

AB - Background: Nausea and vomiting is one of the most feared side effects of chemotherapy; however, in the past 20 years, a better understanding of the pathophysiology of chemotherapy-induced nausea and vomiting (CINV) has led to the introduction of newer antiemetics, which have improved the management of this side effect. Objective: This article reviews the prevention of CINV and the role of aprepitant, the first of the newest class of antiemetics, the neurokinin-1 inhibitors. A brief description of the pathophysiology of CINV and the background on the prevention of CINV using the 5-HT3 antagonists is outlined. The pharmacology, pharmacokinetics, drug interactions and various clinical studies with aprepitant are reviewed. Methods: The literature about aprepitant is reviewed focusing on the role of aprepitant in the management of CINV in relationship to other commonly used antiemetics. The literature was searched regarding aprepitant and its pharmacological characteristics, pharmacokinetics, drug interactions and various clinical studies. Conclusion: Aprepitant has a significant role in the management of CINV, as it allows the majority of patients to complete their chemotherapies without significant morbidity. Its use in a variety of clinical settings in cancer patients needs to be further explored.

KW - Aprepitant

KW - Chemotherapy-induced nausea and vomiting

KW - Clinical studies

KW - Drug interaction

KW - Neurokinin-1 inhibitors

KW - Pharmacokinetics

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=71049138916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049138916&partnerID=8YFLogxK

U2 - 10.1517/17425250903451675

DO - 10.1517/17425250903451675

M3 - Article

C2 - 19929449

AN - SCOPUS:71049138916

VL - 5

SP - 1607

EP - 1614

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 12

ER -